ODT Staff03.03.22
OSSIO Inc. has expanded its OSSIOfiber product line through a three-year contract with Vizient.
Under the agreement, OSSIO's bio-integrative OSSIOfiber products will be available to negotiated pricing to healthcare providers participating in Vizient's group purchasing organization (GPO), beginning March 1. “Our contract with Vizient enables increased access through negotiated pricing to OSSIOfiber technology for thousands of U.S. hospitals and surgery centers,” said OSSIO Chief Commercial and Operating Officer Brennan Marilla. “Our strong and biointegrative fixation products provide patients durable fixation and natural healing, which addresses many of the complications and costs associated with permanent metal fixation, including secondary hardware removal procedures.”
OSSIO’s contract with Vizient covers the OSSIOfiber Intelligent Bone Regeneration Technology portfolio, currently being sold on the market. These products include sterile, disposable instrument kits:
OSSIOfiber products are now available to all members of Vizient at contracted pricing. Vizient is the largest member-driven health care performance improvement company in the country with a diverse membership and customer base including academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute healthcare providers.
“We are thrilled to receive a contract from Vizient for OSSIOfiber implants,” Marilla added, “and hope to help Vizient members care for their patients through the adoption of this technology.”
Founded in 2014, OSSIO aims to provide the first credible replacement to metal implants in the global orthopedic fixation market with its OSSIOfiber Intelligent Bone Regeneration Technology. OSSIO’s is headquartered in Caesarea, Israel, and has a commercial facility in Woburn, Mass.
Under the agreement, OSSIO's bio-integrative OSSIOfiber products will be available to negotiated pricing to healthcare providers participating in Vizient's group purchasing organization (GPO), beginning March 1. “Our contract with Vizient enables increased access through negotiated pricing to OSSIOfiber technology for thousands of U.S. hospitals and surgery centers,” said OSSIO Chief Commercial and Operating Officer Brennan Marilla. “Our strong and biointegrative fixation products provide patients durable fixation and natural healing, which addresses many of the complications and costs associated with permanent metal fixation, including secondary hardware removal procedures.”
OSSIO’s contract with Vizient covers the OSSIOfiber Intelligent Bone Regeneration Technology portfolio, currently being sold on the market. These products include sterile, disposable instrument kits:
- OSSIOfiber Hammertoe Fixation System—10-degree and straight implants in 2.5mm, 2.9mm and 3.2mm sizes.
- OSSIOfiber Trimmable Fixation Nails—Solid-core in 2.4mm and 4.0mm sizes and cannulated in 3.0mm and 4.0mm sizes.
- OSSIOfiber Compression Screws—Headless, cannulated, partially threaded configurations in 4.0mm diameter and lengths from 26–60mm.
OSSIOfiber products are now available to all members of Vizient at contracted pricing. Vizient is the largest member-driven health care performance improvement company in the country with a diverse membership and customer base including academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute healthcare providers.
“We are thrilled to receive a contract from Vizient for OSSIOfiber implants,” Marilla added, “and hope to help Vizient members care for their patients through the adoption of this technology.”
Founded in 2014, OSSIO aims to provide the first credible replacement to metal implants in the global orthopedic fixation market with its OSSIOfiber Intelligent Bone Regeneration Technology. OSSIO’s is headquartered in Caesarea, Israel, and has a commercial facility in Woburn, Mass.